{"Symbol": "CPXX", "AssetType": "Common Stock", "Name": "Celator Pharmaceuticals Inc", "Description": "DELISTED - Celator Pharmaceuticals, Inc. is a United States-based Company which develops therapies for cancer. The Company develops a pipeline of chemotherapies to treat acute myeloid leukemia, colorectal cancer, and small cell lung cancer. Its technology platform identifies synergistic ratios of drugs to improve tumor cell kill and locks the synergistic ratio in a drug delivery vehicle to maintain the ratio in patients. It develops chemotherapies using experimental drugs and develops products that target a range of serious illnesses.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "200 PrincetonSouth Corporate Center, Suite 180\n08628,Ewing,USA\n", "FullTimeEmployees": "None", "FiscalYearEnd": "December", "LatestQuarter": "None", "MarketCapitalization": "0", "EBITDA": "0", "PERatio": "None", "PEGRatio": "0", "BookValue": "0", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.59", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "25", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "0", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "0", "200DayMovingAverage": "0", "SharesOutstanding": "0", "SharesFloat": "0", "SharesShort": "0", "SharesShortPriorMonth": "0", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}